Binder Steven B. sold $128K of MNKD

Binder Steven B. sold 39,051 shares of MANNKIND CORP (MNKD) at $3.29 ($0.13M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Binder Steven B.
Published Sep 29, 2026, 12:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MNKD
Neutral
high confidence
Mentioned
$MNKD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNKDNeutralLow
01

Why it matters

A modest insider sell may cause short‑term price softness, but the overall impact is limited given the small dollar amount.

02

Market read

Primary disclosure of a small insider sale; low trading relevance.

03

What to watch

The director remains a large holder (over 700k shares), suggesting continued confidence.

Relevance 3/10Novelty 3/10Timing: after‑hours filing

Background

SEC Form 4 filing discloses insider transactions; such filings are required to be reported promptly.

Company-level read

Ticker impact

$MNKDNeutralHigh confidence
Context

Director Binder Steven B. sold 39,051 shares for $128,477 via a 10b5‑1 plan, reducing his stake to 713,258 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sell

Evidence & confidence

Form 4 is a primary source; the transaction size is modest, so impact is limited.

Market effects

Minimal; ManKind operates in the cannabis sector, but a small insider sale does not affect sector outlook.

None; the filing is company‑specific.

None

Counterpoint

The sale could be routine under a pre‑arranged plan and not indicative of future weakness.

Key entities

  • ManKind Corp.

    US‑listed cannabis company (ticker MNKD).

  • Binder Steven B.

    Director of ManKind Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MNKDMed

MannKind (MNKD) Q3 2026 Earnings Call Transcript

MannKind (MNKD) reported Q3 2026 revenue of $101.9M, up 24% YoY. Furoscix ReadyFlow approval drove strong adoption, with 75% of prescriptions converted. Afrezza pediatric launch exceeded forecasts, with total prescriptions up 17% sequentially. The company anticipates $15M in milestones from ralinepag DPI in 2027 and key clinical data for nintedanib DPI in early 2028. MannKind closed a $50M private placement, funding a $45M CVR payment.

$MNKDMed

Cantor Fitzgerald raises MannKind stock price target to $10 on Tyvaso momentum

Cantor Fitzgerald raised its price target for MannKind Corp. (NASDAQ:MNKD) to $10.00, citing momentum for Tyvaso DPI and a delayed competitor. The firm expects profitability in 2026, with revenue growth of 30% and a 75% gross margin. MannKind reported Q3 2026 revenue of $101.9M, missing estimates but showing a smaller loss than expected. The company's commercial products and royalties drove growth.

$MNKDHigh

MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update

MANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update • Q3 2026 total revenues of $101.9 million, +24% vs. Q3 2025 • Q3 2026 commercial product revenue of $45.0 million, +102% vs. Q3 2025 o Furoscix ReadyFlow ™ was approved and shipments commenced mid

$MNKDMedAI 8/10

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.

MannKind (MNKD) presented clinical data at HFSA 2026 showing Furoscix ReadyFlow's comparable urine output to IV furosemide. The autoinjector delivers an 80 mg/mL dose in under 10 seconds, with 91.3% and 92.7% bioavailability in thigh and upper-arm injections, respectively. ReadyFlow received FDA approval in July 2026 for fluid overload treatment in heart failure or CKD patients.